3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Breast
31
Tumor-Agnostic
4
Thoracic
3
Gynecologic
3
Gastrointestinal
2
Endocrine
2
Other solid neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Multiple Endocrine Neoplasia Type 1
5
Breast Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Neoplasms by Site
1
Hyperglycemia
1
Breast Diseases
1
Interventions
Doxorubicin
4
Sunitinib
3
Radiosurgery
3
Everolimus
3
pembrolizumab
2
exemestane
2
Tamoxifen
2
Specimen Handling
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Fulvestrant
2
Filgrastim
2
Biopsy
2
Bevacizumab
2
3-Iodobenzylguanidine
2
tislelizumab
1
surufatinib
1
romidepsin
1
regorafenib
1
penpulimab
1
pasireotide
1
mercaptoundecahydrododecaborate
1
lutetium Lu 177 dotatate
1
lanreotide
1
ganitumab
1
folfirinox
1
fludarabine phosphate
1
epothilone B
1
entrectinib
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Fulvestrant
×
Endocrine
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT02753686
2023-02-15
Treat ER+ight
Novartis
Completed
440 enrolled